Trofinetide: First Approval

Collins BE, Neul JL. Rett syndrome and MECP2 duplication syndrome: disorders of MeCP2 dosage. Neuropsychiatr Dis Treat. 2022;18:2813–35.

Article  PubMed  PubMed Central  Google Scholar 

Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020;4(1): e000717.

Article  PubMed  PubMed Central  Google Scholar 

Kyle SM, Vashi N, Justice MJ. Rett syndrome: a neurological disorder with metabolic components. Open Biol. 2018;8(2): 170216.

Article  PubMed  PubMed Central  Google Scholar 

Neul JL, Percy AK, Benke TA, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022. https://doi.org/10.1016/j.cct.2022.106704.

Article  PubMed  Google Scholar 

Neuren Pharmaceuticals Ltd. Annual Report 2021; 2022. https://www.neurenpharma.com/. Accessed 28 Mar 2023.

Panayotis N, Ehinger Y, Felix MS, et al. State-of-the-art therapies for Rett syndrome. Dev Med Child Neurol. 2023;65(2):162–70.

Article  PubMed  Google Scholar 

Silva-Reis SC, Sampaio-Dias IE, Costa VM, et al. Concise overview of glypromate neuropeptide research: from chemistry to pharmacological applications in neurosciences. ACS Chem Neurosci. 2023;14(4):554–72.

Article  CAS  PubMed  Google Scholar 

US FDA. FDA approves first treatment for Rett syndrome [media release]; 13 Mar 2023. https://www.fda.gov/.

Acadia Pharmaceuticals Inc. Trofinetide: US prescribing information; 2023. https://daybue.com/. Accessed 14 Mar 2023.

Neuren Pharmaceuticals Ltd. FDA approval of DAYBUE™ (trofinetide)–the first approved treatment for Rett syndrome [media release]; 13 Mar 2023. https://www.neurenpharma.com/.

Neuren Pharmaceuticals Ltd. Neuren pipeline; 2023. https://www.neurenpharma.com/. Accessed 29 Mar 2023.

Glaze DG, Neul JL, Percy A, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37–46.

Article  PubMed  Google Scholar 

Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92(16):e1912–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berry-Kravis E, Horrigan JP, Tartaglia N, et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Fragile X syndrome. Pediatr Neurol. 2020;110:30–41.

Article  PubMed  Google Scholar 

Acadia Pharmaceuticals Inc, Neuren Pharmaceuticals Ltd. Acadia Pharmaceuticals and Neuren Pharmaceuticals announce exclusive license agreement for the North American development and commercialization of trofinetide in Rett Syndrome [media release]; 6 Aug 2018. https://acadia.com/.

Acadia Pharmaceuticals Inc. Form 10-K; 2022. https://ir.acadia.com/. Accessed 28 Mar 2023.

Bickerdike MJ, Thomas GB, Batchelor DC, et al. NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J Neurol Sci. 2009;278(1–2):85–90.

Article  CAS  PubMed  Google Scholar 

Tropea D, Giacometti E, Wilson NR, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci USA. 2009;106(6):2029–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deacon RM, Glass L, Snape M, et al. NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for Fragile X syndrome. Neuromolecular Med. 2015;17(1):71–82.

Article  CAS  PubMed  Google Scholar 

Darwish M, Harlick J, Youakim J, et al. A phase 1, ascending dose study to assess the potential effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults [abstract no. 212]. Ann Neurol. 2022;92(Suppl 28):S174.

Google Scholar 

Darwish M, Youakim JM, Harlick J, et al. A phase 1, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42(6):513–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Percy A, Berry-Kravis E, Lieberman D, et al. Trofinetide for the treatment of Rett syndrome: an open-label study in girls 2 to 4 years of age [abstract no. P13.9-005]. In: American Academy of Neurology (AAN) Annual Meeting; 2023.

Neul J, Percy A, Benke T, et al. Efficacy and safety of trofinetide for the treatment of females with Rett syndrome: results from the randomized, double-blind, phase 3 LAVENDER study [abstract no. 191]. Ann Neurol. 2022;92(Suppl 28):S162–3.

Google Scholar 

Acadia Pharmaceuticals Inc. 2023 (Data on file).

留言 (0)

沒有登入
gif